Array ( [slideid] => 2 [autoload] => 1 [effect] => scrollUp [speed] => 5000 [width] => 470 [height] => 124 )

Array ( [slideid] => 1 [autoload] => 1 [effect] => fade [speed] => 10000 [width] => 640 [height] => 300 )
  • Alteplase is safe and effective for use within existing treatment guidelines

    Independent expert review concludes alteplase is safe and effective for use within existing treatment guidelines An in-depth independent expert review of a clot-busting drug used in the treatment of acute ischaemic stroke has provided a firm reassurance that it is safe and effective for use – up to 4.5 hours after the onset of symptoms. The earlier the treatment is given the greater the chance of a more favourable outcome for patients. Alteplase acts by breaking down blood clots and can benefit patients by restoring blood flow to areas of the brain that have been affected by a stroke, thereby reducing the risk of long-term disability. An independent expert working group of the UK’s Commission on Human Medicines (CHM) was formed to consider the latest data on the benefits and risks of alteplase in strokes, with a particular focus on the time window for effective treatment. This was in response to questions raised about the evidence base for treatment. The independent scientific group, chaired by Professor Sir Ian Weller, comprised members with expertise in neurology, cardiology, emergency medicine, statistics, epidemiology and patient representation. Following a review of all the latest available evidence the group reached the following conclusions:  The benefit of using alteplase outweighs the risk when used up to 4.5 hours after the onset of symptoms in accordance with the licence. The benefit of alteplase in the treatment of stroke is highly time-dependent and therefore minimising the time to the start of treatment is critical to ensuring the best possible outcome. The latest available data strengthen the existing evidence base for the current authorised use of alteplase.   Professor Sir Ian Weller said: “Patients, the public and healthcare professionals should be reassured that the independent expert working group has rigorously reviewed and discussed all available data and unanimously concluded that alteplase remains safe and effective for use in the treatment of acute ischaemic stroke. “The evidence shows that for every 100 patients treated with alteplase, whilst there is an early risk of a fatal bleed in 2 patients, after three to six months, around 10 more in every 100 are disability free when treated within three hours. In addition 5 more patients in every 100 are disability free when treated between 3 and 4.5 hours after a stroke.  “The conclusion of the group is very clear in that the current timeframe for treatment is supported by strong evidence. The MHRA’s Director of Vigilance and Risk Management of Medicines Dr June Raine said: “A thorough scientific assessment was conducted by staff not involved in the licensing of alteplase. They reviewed all the latest available evidence. We will continue to monitor the safety of alteplase and if any new evidence emerges we will reassess the benefit-risk balance. Patients treated with alteplase should be reassured that this continues to be an effective medicine when used within 4.5 hours after the onset of stroke symptoms.”  Ends  Notes to Editors 1.The Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for regulating all medicines and medical devices in the UK by ensuring they work and are acceptably safe. All our work is underpinned by robust and fact-based judgements to ensure that the benefits justify any risks. MHRA is a centre of the Medicines and Healthcare products Regulatory Agency which also includes the National Institute for Biological Standards and Control (NIBSC) and the Clinical Practice Research Datalink (CPRD). The Medicines and Healthcare products Regulatory Agency is an executive agency of the Department of Health.  2.The Commission on Human Medicines (CHM) is a non-departmental public body that advises ministers on the safety, efficacy and quality of medicinal products.    
  • YoungStroke 2015

    Dear Members of the WSO Board of Directors, We are rarely afforded an opportunity to be a part of a unique international event such as YoungStroke 2015 – a continuing medical education forum highlighting stroke in young adults scheduled June 27-29, 2015 at Omni Jacksonville in Jacksonville, Florida.  Proudly endorsed by the World Stroke Organization, YoungStroke 2015 aims to raise awareness, increase knowledge and share good practice about stroke in young adults. Through both didactic lectures and interactive workshops by an exceptional array of global experts, YoungStroke 2015 targets the critical issues surrounding management and treatment of the young adult stroke patients under 65. View full agenda and register:      Indeed, YoungStroke 2015 will be an exciting event and you are warmly invited. The increasing global prevalence of stroke marks this event as both timely and necessary. Each year, approximately 30% of people who suffer a stroke are under age 65. This number now exceeds 50% in parts of America’s Stroke Belt region where stroke mortality consistently ranks highest in the nation. Too many young stroke patients experience misdiagnosis and delayed access to care. Stroke also poses particularly devastating financial and physical burdens for young survivors as they face overwhelming challenges to regain independence and return to their professional roles and family responsibilities. Your participation would contribute much toward the engagement of our stroke community in provocative and concentrated discourse to propel research and best practices for this distinctive population. Be part of a great work … join us at YoungStroke 2015! Stephen Davis                                                                                 Bo Norrving                 WSO President                                                                               WSO Immediate Past-President
  • World Hypertension Day - 17 May 2015

    Press Release:  Knowing and treating your blood pressure dramatically reduces your risk for stroke.   World Hypertension Day│17 May 2015 – On World Hypertension Day 2015, the World Stroke Organization call for a scale up in blood pressure screening around the world. Hypertension is the single most important risk factor for stroke. The greatest challenge is that hypertension is often undetected, and even when diagnosed, often untreated or inadequately managed. With lifestyle changes and modern drug therapies, hypertension is entirely manageable if detected. So, it plays an incredibly significant role in the fight against stroke worldwide.   “Hypertension typically has no associated symptoms and can affect people of all ages. It is the most important risk factor for stroke that we can control. Therefore, everybody should know their BP numbers,” says WSO President Stephen Davis.  One of the primary aims of the World Hypertension League (WHL) this year is their challenge to screen over 1 million people by May 17 2015. We encourage all WSO members to support World Hypertension Day in whatever capacity possible, but most importantly by promoting screening to help achieve this goal. For more information please visit About the World Stroke Organization The World Stroke Organization (WSO) was established in October 2006. WSO’s mission is to reduce the global burden of stroke through prevention, treatment and long-term care. As the leading international body for stroke, WSO aims to accomplish its mission by: Fostering the best standards of practice Increasing stroke awareness among the population and among health professionals Preventing subtle cerebrovascular disease leading to gait disorders, imbalance, vascular cognitive impairment and behavioral changes Influencing policies for stroke prevention and improved health services Providing education in collaboration with public and private organizations Facilitating stroke research advocacy for people with stroke Fostering the development of systems and organizations for long-term care and support of stroke survivors and their families. With individual and organizational members worldwide, including stroke support groups, WSO is the global voice for stroke. WSO is the only international stroke NGO in official relations with the World Health Organization (WHO). Prof. Stephen Davis, MD, FRCP, Edin FRACP, from Melbourne, Australia, is the President of the World Stroke Organization. Contact World Stroke Organization Geneva, Switzerland Tel: +41 22 906 9129 Email: This email address is being protected from spambots. You need JavaScript enabled to view it. To download the press release, please click here.
  • Finalists Inspiration Vocal Competition

    Finalists for the Inspiration Vocal Competition  Entry #1: Leslie Ann Huggins   Be inspired by Leslie Ann Jolly Huggins, 39, of San Fernando, TRINIDAD …young stroke survivor since May 13, 2011.  Entry #2: Noelia Chumpitaz Be inspired by Noelia Chumpitaz, 31, of Charlotte, North Carolina, UNITED STATES ... young stroke survivor since June 30, 2013. Amy Edmunds  Survivor since 2002 / Founder & CEO This email address is being protected from spambots. You need JavaScript enabled to view it. 843.655.2835    Skype: YoungStroke

wsa logo color The World Stroke Academy (WSA) is a elearning portal for the World Stroke Organization (WSO). it provides stroke information on a dynamic, and award-winning online, elerning platform for healthcare professionals with an aim to alleviate the global burden of stroke through the education of stroke practitioners worldwide.
The World Stroke Campaign (WSC) provides education and support for stroke survivors, families and healthcare professional involved in stroke treatment, management and rehabilitation. The primary focus of the WSC is the annual World Stroke Day (WSD), promoting stroke awareness to the international community and working towards pushing stroke to the forefront of the global health agenda.
Hyderabad thumnail Hyderabad, India, October 26- 29, 2016
Through its biennial congresses, the World Stroke Organization (WSO) strives to offer participants opportunities to refine their skills and knowledge in the field of stroke, as well as providing excellent networking opportunities and strengthening scientific collaborations to improve the care of stroke victims throughout the world.
IJS frontcover thumbnail
The International Journal of Stroke (IJS) is the flagship publication of the World Stroke Organization (WSO) and publishes high quality research articles, reviews and clinical trial protocols from around the world. IJS is dedicated to building a global stroke community, making it a global voice for stroke research and an excellent platform for sharing international stroke research.
Stay connected with us through Twitter, the WSO blog, and YouTube!

Stroke Support Organizations have a key role in supporting stroke survivors and their carergivers! Below a message of hope and courage from stroke survivors in the form of artwork.


Your membership makes the difference! Have a look at the video to find out more.